The advent of intravitreal treatment with anti-vascular endothelium growth factor (anti-VEGF) antibodies and steroids has revolutionized the management of diabetic retinopathy. This timely 2nd edition delves into therapies involving anti-VEGF, and addresses the complexities inherent in the practical application of these clinical trials, from issues of patient compliance, to consideration of the patient's overall health status. Clinical Strategies in the Management of Diabetic Retinopathy: Step-by-Step Guide for Ophthalmologists, 2nd Edition covers all the stages of diabetic retinopathy,…mehr
The advent of intravitreal treatment with anti-vascular endothelium growth factor (anti-VEGF) antibodies and steroids has revolutionized the management of diabetic retinopathy. This timely 2nd edition delves into therapies involving anti-VEGF, and addresses the complexities inherent in the practical application of these clinical trials, from issues of patient compliance, to consideration of the patient's overall health status.
Clinical Strategies in the Management of Diabetic Retinopathy: Step-by-Step Guide for Ophthalmologists, 2nd Edition covers all the stages of diabetic retinopathy, including clinical manifestations, imaging, and treatment, from the early signs to more advanced levels of severity. Richly-illustrated, this clinical resource is designed to present multiple practical and useful suggestions for the management of each stage of diabetic retinopathy, using algorithms, tables, and summaries. Images of sample cases exemplify the effects of differenttherapies, including benefits and side effects. Novel perspectives in both imaging and treatment are provided to clearly outline current research in the field, with a look to future directions. Written and edited by well-respected leaders in the field, Clinical Strategies in the Management of Diabetic Retinopathy, 2nd edition is an ideal resource for ophthalmologists aiming to provide optimal clinical management for this sight-threatening disease.
Francesco Bandello, MD, FEBO is Professor and Chairman of the Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy. He serves as Academic Dean at his University. He is President of Euretina, Vice President of Academia Ophthalmologica Europea, Fellow of the European Leadership Development Programme of the American Academy of Ophthalmology and a former Executive Committee Member of The Macula Society and of the Club Jules Gonin. Dr. Bandello is Associate Editor of the European Journal of Ophthalmology and Editor of Developments in Ophthalmology (Karger, Basel). Dr. Bandello is also an editorial board member of several other journals, including JAMA Ophthalmology, Case Reports in Ophthalmology, Journal of Ocular Pharmacology and Therapeutics and Ophthalmologica. He has been principal investigator in several clinical trials mainly focusing on age-related macular degeneration and diabetic retinopathy. Dr. Bandello has published 220 articles in peer-reviewed journals and is the co-author of seven books. Marco Attilio Zarbin, MD, PhD, FACS was appointed chair of the Institute of Ophthalmology and Visual Science, New Jersey Medical School and chief of ophthalmology at University Hospital in Newark, N.J., in 1994. He is a professor of ophthalmology and neuroscienceat the New Jersey Medical School and holds the Alfonse A. Cinotti,MD/Lions Eye Research Chair in the Department of Ophthalmology. Dr. Zarbin is also co-director of the Ocular Cell Transplantation Laboratory and the co-director of the Center for Macular Degeneration Research at UMDNJ. His research is focused on developing new surgical treatments for age-related macular degeneration, the leading cause of blindness in persons over age 55 in the United States and Western Europe. He is the editor-in-chief of Translational Vision Science and Technology, and has served as associate editor of Investigative Ophthalmology and Visual Science and as a member of the editorial board of Survey of Ophthalmology. Dr. Zarbin is a vice chair of the Scientific Advisory Board of the Foundation Fighting Blindness and is an ex officio member of the board of Governors of the New Jersey Academy of Ophthalmology and the National Advisory Eye Council of the National Institutes of Health. In addition, he is a member of the American Ophthalmological Society, the Retina Society, the Macula Society and the Vitreous Society and is past president of the board of trustees of the Association of University Professors of Ophthalmology (AUPO) and has served as the alternate AUPO representative to the Council of the American Academy of Ophthalmology. Dr. Zarbin has been listed among the "Best Doctors in America," as well as among the "Best Doctors in New Jersey" and the "Best Doctors in New York." Ilaria Zucchiatti, MD is currently a Consultant at the Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy, having previously completed her specialization in ophthalmology. Her specific research interest involves age related macular degeneration and diabetic retinopathy. She has been Study Coordinator for various randomized clinical trials relating to retinal diseases. Dr. Zucchiatti has to date authored sixteen articles in peer-reviewed journals. Rosangela Lattanzio, MD is a member of the Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy and Head of the Medical Retina Service-Vasculopathies at San Raffaele Hospital. Since 2002 she has been an Editorial Associate of the European Journal of Ophthalmology. From 2008 to 2010, Dr. Lattanzio served on the Scientific Committee of the Italian Society of Ophthalmology. Her particular research interest is the retina (vasculopathies, diabetic retinopathy, retinal vein occlusions, etc.). She was awarded in 2004 Kreissig award-Euretina and in 2007 First Prize by the Italian Society of Ophthalmology for a research project. Dr. Lattanzio is an elected member of the Club Jules Gonin. She has been principal investigator or study coordinator in several clinical trials mainly focusing on retinal vasculopathies. Dr. Lattanzio is the author of numerous articles in peer-reviewed journals and is the co-author of one book.
